• Notable sales growth in instrument business
• Significant increase of operating profit (EBIT) and cashflow
  
• Earnings per share with EUR 0.51 at previous year's level

Jena/Germany, December 17, 2009 — With the best result since foundation of the Company, Analytik Jena AG (Frankfurt DE0005213508, Prime Standard: AJA) successfully completed financial year 2008/2009 as of September 30, 2009.

The provider of analytical, bioanalytical, and optical systems generated revenue in instrument business of EUR 71,132 thousand (previous year: EUR 53,079 thousand). Taking into account the acquired subsidiaries CyBio AG and Biometra GmbH this means an increase of 34.0%. The organic revenue growth corresponds to the Company put on 10.3%.

"The strategic direction of Analytik Jena with the focus on the instrument business, sensible company acquisitions, and the essential reinforcement of sales structures, is effective. Despite an extremely difficult economic environment, we were able to continue to generate strong growth in terms of revenue and EBIT. We see this as testimony to the strength of our business model", said Klaus Berka, CEO of Analytik Jena AG.

Particularly in its core analytical solutions and bio solutions business units, the Company significantly boosted its revenue. With revenue of EUR 46,635 thousand (previous year: EUR 40,225 thousand), the analytical solutions business unit was able to increase the previous year's record revenue again by a significant 15.9%. In particular, new innovative products in the premium-price segment and revenue increase in the Chinese market were able to compensate somewhat for overall global investment restraint.

The bio solutions business unit recorded revenue of EUR 17,876 thousand (previous year: EUR 4,317 thousand). This quadrupling of revenue was for the most part attributable to the integration of the CyBio AG and Biometra GmbH subsidiaries. However, the business unit also achieved a strong organic growth of 22.1%.

Consumer restraint linked to the macroeconomic environment affected in particular the optical solutions business unit, which, given its consumer-oriented target groups, expectedly was unable to maintain its 12-year long upward trajectory. With a slight increase in margin, revenue in the optical solutions business unit in the past financial year totaled EUR 6,621 thousand (previous year: EUR 8,537 thousand), reflecting a decline of 22.4%.

The Group has an export ratio of 67.0% (previous year: 73.0%) and the Asia region continues to expand its position as the largest foreign sales market. Goods amounting to EUR 23,276 thousand were exported to this region (previous year: EUR 15,770 thousand). Taking into account the acquired subsidiaries CyBio AG and Biometra GmbH, the Group's revenue within Germany increased by 27.4% to EUR 23,451 thousand (previous year: EUR 18,403 thousand).

Analytik Jena achieved solid results again in the past financial year. Earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 36.4% to EUR 9,400 thousand (previous year: EUR 6,893 thousand). The operating result (EBIT) rose by about 34.1% to EUR 6,316 thousand (previous year: EUR 4,709 thousand), which corresponds to an EBIT margin of 8.9% compared with 8.9%, taking only the continued instrument business unit into account. Earnings before tax (EBT) advanced by 58.0% from EUR 2,857 thousand in the previous year to EUR 4,513 thousand in the period under review. The net profit for the year increased at a much lower 12.8% to EUR 2,706 thousand (previous year: EUR 2,399 thousand). This result was particularly encumbered by very high tax expenses of EUR 1,807 thousand compared to the previous year (EUR 458 thousand), which corresponds to a tax rate of 40.0% (previous year: 16.0%). This result was mainly caused by the fact, that high profits were diminished by losses at our subsidiary AJ Japan, for which no deferred tax assets could be recognized as of the balance sheet date. Furthermore, the net profit for the year was negatively affected by the loss associated with the investment in AJZ Engineering of EUR -929 thousand (previous year: EUR -451 thousand). Due to these effects both basic and diluted earnings per share were unchanged compared to the previous year at EUR 0.51 per share.

Analytik Jena's total assets as of the balance sheet date on September 30, 2009 increased from EUR 57,418 thousand to EUR 75,465 thousand as a result of the acquisitions completed in the past financial year. Cash flow from operating activities increased by EUR 6.193 thousand to EUR 4,531 thousand (previous year: EUR -1,662 thousand).

As of September 30, 2009, the Group had a total of 773 employees, including 54 interns (previous year: 536 employees, including 48 interns).

"The Group's strategic focus in the current financial year and beyond will be on the integration of the new subsidiaries CyBio AG and Biometra GmbH into the bio solutions business unit and the combined approach towards the major growth area of life science. The goal is to expand international sales and distribution network further and to leverage fully the experience and structures of analytical solutions for other business units", Berka added.

Analytik Jena anticipates that it will maintain overall growth in the current financial year.

The complete annual report is available at
www.analytik-jena.de/AnnualReport0809.pdf.